Vyteris Announces Positive Results From Phase II Clinical Trial of Transdermal Patch for Female Infertility
Links shared publicly online about this topic.
- 958total visits
Vyteris Announces Positive Results From Phase II Clinical Trial of Transdermal Patch for Female Infertility
Vyteris, Inc. (OTCBB: VYTR), developer of the first FDA-approved active transdermal patch and a leader in alternative drug delivery technology, today announced positive results from a Phase II clinical trial evaluating the safety and efficacy of a pulsatile delivery system for the treatment of female infertility, based on the Company's smart patch technology.
View full resource at marketwire.com
Tags: Infertility, Drug, Clinical Trial, Women's Health, Safety
Most Recently Shared on August 10, 2010 at 5:14 pm By:
Vyteris Announces Positive Results From Phase II Clinical Trial of Transdermal Patch for Female Infertility: FAIR ... http://bit.ly/aEtC1U
Vyteris announces phase II trial results of transdermal patch for female infertility - Clinical Trials
pharmabiz.com — “Vyteris, Inc., developer of the first FDA-approved active transdermal patch and a leader in alternative drug delivery technology, announced positive results from a phase II clinical trial evaluating the safety and efficacy” View full resource at pharmabiz.com
Most Recently Shared on August 13, 2010 at 10:48 am By:
Vyteris announces phase II trial results of transdermal patch for female infertility: Vyteris, Inc., developer of ... http://bit.ly/br3w2X
Advertisement
